Anticancer therapy: boosting the bang of Bim. (scientific article published on 23 October 2008)

MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol

Q40537978

Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover

Q40606380

Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.

Q40626751

Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro

Q40636311

Bcl-2 phosphorylation required for anti-apoptosis function

Q41111068

Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix

Q24537504

Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions

Q28513666

The BCL-2 protein family: opposing activities that mediate cell death

Q29547380

BRAF mutation predicts sensitivity to MEK inhibition

Q29614281

BRAF as a potential therapeutic target in melanoma and other malignancies

Q35212513

Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow

Q35773852

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Q36612290

Bcl-2-regulated apoptosis: mechanism and therapeutic potential

Q36880621

Recent advances of MEK inhibitors and their clinical progress

Q36907524

Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic

Q36945203

Is B-Raf a good therapeutic target for melanoma and other malignancies?

Q37048982

How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?

Oncogene addiction

issue

language of work or name

English

Q1860

P304

page(s)

3582-3584

P577

publication date

2008-10-23

P1433

published in

Journal of Clinical Investigation

Q3186904

P1476

title

Anticancer therapy: boosting the bang of Bim.

P478

volume

118

Reverse relations

cites work (P2860)

Q35799771	A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer.
Q36425600	ABT-737 synergizes with Bortezomib to kill melanoma cells
Q42964537	Bim regulation miRrors microRNA 17∼92 cluster expression in endothelial cells in vivo
Q33808800	Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells
Q38323233	Inhibition of CRM1-mediated nucleocytoplasmic transport: triggering human melanoma cell apoptosis by perturbing multiple cellular pathways
Q47624759	Measurement of BH3-only protein tolerance.
Q37782497	Molecular pathways regulating CD4+ T cell differentiation, anergy and memory with implications for vaccines
Q49317830	Overexpression of microRNA-1470 promotes proliferation and migration, and inhibits senescence of esophageal squamous carcinoma cells
Q33569854	Protein kinase Cbeta modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy.
Q35004008	Selumetinib produces a central core of apoptosis in breast cancer bone metastases in mice
Q38932682	miR-146a and miR-370 coordinate enterovirus 71-induced cell apoptosis through targeting SOS1 and GADD45β.
Q36545095	t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib